Forfenimex |CAS#71522-58-2 |low molecular weight immunomodifier

MedKoo Cat#: 584167 | Name: Forfenimex

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Forfenimex is a newly discovered low molecular weight immunomodifier.

Chemical Structure

Forfenimex

CAS#71522-58-2

Theoretical Analysis

MedKoo Cat#: 584167

Name: Forfenimex

CAS#: 71522-58-2

Chemical Formula: C9H11NO4

Exact Mass: 197.0688

Molecular Weight: 197.19

Elemental Analysis: C, 54.82; H, 5.62; N, 7.10; O, 32.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Forfenimex; BF 121; BF121; BF-121.

IUPAC/Chemical Name

(+)-(S)-2-(alpha,3-Dihydroxy-p-tolyl)glycine

InChi Key

JRBXPUUAYKCCLQ-QMMMGPOBSA-N

InChi Code

InChI=1S/C9H11NO4/c10-8(9(13)14)5-1-2-6(4-11)7(12)3-5/h1-3,8,11-12H,4,10H2,(H,13,14)/t8-/m0/s1

SMILES Code

N[C@@H](C1=CC=C(CO)C(O)=C1)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 197.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Murphy KT, Wardak A, Beckett MA, Lopez CA, Mehta N, Kimchi E, Salloum RM, Jaskowiak NT, Posner MC, Ohno T, Kufe DW, Weichselbaum RR, Mauceri HJ. Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Cancer Chemother Pharmacol. 2005 Sep;56(3):317-21. Epub 2005 May 11. PubMed PMID: 15887016. 2: Tanaka M, Hori Y, Sakai F, Ueda H, Goto T, Okuhara M, Tsuda Y, Okada Y. WS1279, a novel lipopeptide isolated from Streptomyces willmorei. Biological activities. J Antibiot (Tokyo). 1993 Nov;46(11):1699-706. PubMed PMID: 8270492. 3: Koyama Y, Huang SP, Ikeda D, Hamada M, Kondo S, Takeuchi T. Orally absorbable D-forphenicinol-cephalosporins. J Antibiot (Tokyo). 1989 Jun;42(6):993-9. PubMed PMID: 2737957. 4: Ishihara K, Hayasaka K, Yamazaki N. Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan. J Invest Dermatol. 1989 May;92(5 Suppl):326S-328s. PubMed PMID: 2469742. 5: Chao WF, Kai M, Ohkura Y. High-performance liquid chromatographic determination of forphenicine in mouse serum and muscle by pre-column fluorescence derivatization using 1,2-diamino-4,5-ethylenedioxybenzene as fluorogenic reagent. J Chromatogr. 1988 Sep 9;430(2):361-7. PubMed PMID: 3235509. 6: Hoeprich PD, Merry JM. Comparative efficacy of forphenicinol, cyclosporine, and amphotericin B in experimental murine coccidioidomycosis. Diagn Microbiol Infect Dis. 1987 Apr;6(4):287-92. PubMed PMID: 3581735. 7: Ishibashi T, Takamoto M, Shinoda A, Kihara H, Nagano H, Kawakami K, Yamato Y, Nakanishi K, Yamamoto T, Otsu T, et al. [Clinical trial of forphenicinol for the lung infection with Mycobacterium avium, Mycobacterium intracellulare complex]. Jpn J Antibiot. 1987 Apr;40(4):711-26. Japanese. PubMed PMID: 3302344. 8: Naito K, Arakawa H, Watanabe Y, Okura A, Ishizuka M, Takeuchi T, Umezawa H. Protective effect of forphenicinol, a low molecular weight immunomodifier, against infection with Pseudomonas aeruginosa in mice and its mechanisms. J Antibiot (Tokyo). 1987 Apr;40(4):547-54. PubMed PMID: 3034847. 9: Okura A, Naito K, Iizuka H, Ishizuka M, Takeuchi T, Umezawa H. Effect of forphenicinol, a low molecular weight immunomodifier, on the growth of and the immune responses to murine lymphoma EL4. J Biol Response Mod. 1987 Feb;6(1):35-43. PubMed PMID: 3559627. 10: Okura A, Nakadaira M, Naito K, Arakawa H, Ishizuka M, Takeuchi T, Umezawa H. Effect of forphenicinol on the production of lipopolysaccharide-induced interferon and tumor necrosis factor and on the growth of Meth A fibrosarcoma in mice. J Biol Response Mod. 1987 Feb;6(1):28-34. PubMed PMID: 2435854. 11: Ohhara N, Okamura S, Otsuka T, Harada M, Niho Y. Stimulatory effect of forphenicinol on normal human bone marrow granulocyte-macrophage progenitor cells mediated by T-lymphocytes. Biomed Pharmacother. 1987;41(8):425-8. PubMed PMID: 3502533. 12: Uchiyama N, Takano T, Saito S, Morikawa H, Ohtawa M. Quantitative determination of forphenicinol and its metabolites in human serum and urine by gas chromatography/mass spectrometry with selected ion monitoring. Chem Pharm Bull (Tokyo). 1986 Aug;34(8):3290-7. PubMed PMID: 3791500. 13: Kai M, Tamura K, Ohno M, Ohkura Y. Simple determination of forphenicinol in human plasma and erythrocytes by HPLC with native fluorescence detection. Biomed Chromatogr. 1986 Aug;1(4):143-6. PubMed PMID: 3506826. 14: Miura K, Sawa T, Takeuchi T, Umezawa H. Effects of enzyme inhibitors in inhibiting the growth and inducing the differentiation of human promyelocytic leukemia cells, HL-60. J Antibiot (Tokyo). 1986 May;39(5):734-5. PubMed PMID: 3460977. 15: Okura A, Sawazaki Y, Naito K, Ishizuka M, Takeuchi T, Umezawa H. Antitumor effect of forphenicinol, a low molecular weight immunomodifier, in combination with surgery on Meth A fibrosarcoma, Lewis lung carcinoma, and adenocarcinoma 755. J Antibiot (Tokyo). 1986 Apr;39(4):564-8. PubMed PMID: 3710915. 16: Okura A, Arakawa H, Yoshinari T, Naito K, Ishizuka M, Takeuchi T, Umezawa H. Effect of forphenicinol on the production of Ia-positive macrophages in mice with or without L1210 leukemia and on the growth of L1210 in immunized mice. J Antibiot (Tokyo). 1986 Apr;39(4):575-80. PubMed PMID: 3458691. 17: Okura A, Nakadaira M, Naito K, Ishizuka M, Takeuchi T, Umezawa H. Effect of forphenicinol on gamma-interferon production in mice sensitized with BCG. J Antibiot (Tokyo). 1986 Apr;39(4):569-74. PubMed PMID: 3011721. 18: Nitta K, Tanaka T. [Enhancement of immune response by an antitumor agent, cyclophosphamide]. Gan To Kagaku Ryoho. 1986 Mar;13(3 Pt 2):706-13. Japanese. PubMed PMID: 2938546. 19: Yoshimura K, Chonabayashi N, Nakatani T, Nakamori Y, Nakata K, Tanimoto H. [Clinical and immunological studies on forphenicinol, a low molecular weight immunomodulator, in chronic respiratory infections]. Kansenshogaku Zasshi. 1985 Oct;59(10):996-1004. Japanese. PubMed PMID: 3936891. 20: Kumano N, Nakai Y, Ishikawa T, Koinumaru S, Suzuki S, Oizumi K, Konno K. Changes in the immunological parameters after a single dose of forphenicinol, a new small molecular immunomodifier. Tohoku J Exp Med. 1985 Aug;146(4):419-27. PubMed PMID: 4071537.